We Offer Worldwide Shipping
Login Wishlist

6-Methoxykaempferol 3-O-rutinoside

$807

  • Brand : BIOFRON

  • Catalogue Number : BD-P0091

  • Specification : 95.0%(HPLC)

  • CAS number : 403861-33-6

  • Formula : C28H32O16

  • Molecular Weight : 624.54

  • PUBCHEM ID : 70694423

  • Volume : 10mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0091

Analysis Method

HPLC,NMR,MS

Specification

95.0%(HPLC)

Storage

2-8°C

Molecular Weight

624.54

Appearance

Yellow powder

Botanical Source

Structure Type

Flavonoids

Category

SMILES

CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=C(C(=C4C3=O)O)OC)O)C5=CC=C(C=C5)O)O)O)O)O)O)O

Synonyms

5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one

IUPAC Name

5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one

Applications

Density

1.74±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

Boiling Point

Melting Point

InChl

InChI=1S/C28H32O16/c1-9-16(31)20(35)22(37)27(41-9)40-8-14-17(32)21(36)23(38)28(43-14)44-26-19(34)15-13(7-12(30)25(39-2)18(15)33)42-24(26)10-3-5-11(29)6-4-10/h3-7,9,14,16-17,20-23,27-33,35-38H,8H2,1-2H3/t9-,14+,16-,17+,20+,21-,22+,23+,27+,28-/m0/s1

InChl Key

FPVLVSUOCXHCMR-FPHOCJSOSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:403861-33-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

403861

Abstract

A procedure is described for the purification of hemagglutinin-free Clostridium botulinum type C toxin. The toxin was purified approximately 1,000-fold from the original culture supernatant in an overall yield of 60% to a final specific toxicity of 4.4 x 10(7) minimal lethal doses/mg of protein. The toxin had a molecular weight of 141,000 and consisted of a heavy and a light chain. The molecular weights of the subunits were approximately 98,000 and 53,000. When comparing the molecular size and composition of type C toxin to that of botulinum toxins of different types, some common features may be suggested; i.e., the toxin has a molecular weight between 141,000 to 160,000 and is comprised of a heavy and a light chain linked by disulfide bonds (or bond).

Title

Isolation and molecular size of Clostridium botulinum type C toxin.

Author

B Syuto and S Kubo

Publish date

1977 Feb;

PMID

28898390

Abstract

Background
Comprehensive geriatric assessment (CGA) is a multi‐dimensional, multi‐disciplinary diagnostic and therapeutic process conducted to determine the medical, mental, and functional problems of older people with frailty so that a co‐ordinated and integrated plan for treatment and follow‐up can be developed. This is an update of a previously published Cochrane review.

Objectives
We sought to critically appraise and summarise current evidence on the effectiveness and resource use of CGA for older adults admitted to hospital, and to use these data to estimate its cost‐effectiveness.

Search methods
We searched CENTRAL, MEDLINE, Embase, three other databases, and two trials registers on 5 October 2016; we also checked reference lists and contacted study authors.

Selection criteria
We included randomised trials that compared inpatient CGA (delivered on geriatric wards or by mobile teams) versus usual care on a general medical ward or on a ward for older people, usually admitted to hospital for acute care or for inpatient rehabilitation after an acute admission.

Data collection and analysis
We followed standard methodological procedures expected by Cochrane and Effective Practice and Organisation of Care (EPOC). We used the GRADE approach to assess the certainty of evidence for the most important outcomes. For this update, we requested individual patient data (IPD) from trialists, and we conducted a survey of trialists to obtain details of delivery of CGA. We calculated risk ratios (RRs), mean differences (MDs), or standardised mean differences (SMDs), and combined data using fixed‐effect meta‐analysis. We estimated cost‐effectiveness by comparing inpatient CGA versus hospital admission without CGA in terms of cost per quality‐adjusted life year (QALY) gained, cost per life year (LY) gained, and cost per life year living at home (LYLAH) gained.

Main results
We included 29 trials recruiting 13,766 participants across nine, mostly high‐income countries. CGA increases the likelihood that patients will be alive and in their own homes at 3 to 12 months’ follow‐up (risk ratio (RR) 1.06, 95% confidence interval (CI) 1.01 to 1.10; 16 trials, 6799 participants; high‐certainty evidence), results in little or no difference in mortality at 3 to 12 months’ follow‐up (RR 1.00, 95% CI 0.93 to 1.07; 21 trials, 10,023 participants; high‐certainty evidence), decreases the likelihood that patients will be admitted to a nursing home at 3 to 12 months follow‐up (RR 0.80, 95% CI 0.72 to 0.89; 14 trials, 6285 participants; high‐certainty evidence) and results in little or no difference in dependence (RR 0.97, 95% CI 0.89 to 1.04; 14 trials, 6551 participants; high‐certainty evidence). CGA may make little or no difference to cognitive function (SMD ranged from ‐0.22 to 0.35 (5 trials, 3534 participants; low‐certainty evidence)). Mean length of stay ranged from 1.63 days to 40.7 days in the intervention group, and ranged from 1.8 days to 42.8 days in the comparison group. Healthcare costs per participant in the CGA group were on average GBP 234 (95% CI GBP ‐144 to GBP 605) higher than in the usual care group (17 trials, 5303 participants; low‐certainty evidence). CGA may lead to a slight increase in QALYs of 0.012 (95% CI ‐0.024 to 0.048) at GBP 19,802 per QALY gained (3 trials; low‐certainty evidence), a slight increase in LYs of 0.037 (95% CI 0.001 to 0.073), at GBP 6305 per LY gained (4 trials; low‐certainty evidence), and a slight increase in LYLAH of 0.019 (95% CI ‐0.019 to 0.155) at GBP 12,568 per LYLAH gained (2 trials; low‐certainty evidence). The probability that CGA would be cost‐effective at a GBP 20,000 ceiling ratio for QALY, LY, and LYLAH was 0.50, 0.89, and 0.47, respectively (17 trials, 5303 participants; low‐certainty evidence).

Authors’ conclusions
Older patients are more likely to be alive and in their own homes at follow‐up if they received CGA on admission to hospital. We are uncertain whether data show a difference in effect between wards and teams, as this analysis was underpowered. CGA may lead to a small increase in costs, and evidence for cost‐effectiveness is of low‐certainty due to imprecision and inconsistency among studies. Further research that reports cost estimates that are setting‐specific across different sectors of care are required.

KEYWORDS

Aged, Humans, Frail Elderly, Hospitalization, Outcome and Process Assessment (Health Care), Comprehensive Health Care, Comprehensive Health Care/methods, Emergencies, Geriatric Assessment, Geriatric Assessment/methods, Independent Living, Mortality

Title

Comprehensive geriatric assessment for older adults admitted to hospital

Author

Graham Ellis,corresponding author Mike Gardner, Apostolos Tsiachristas, Peter Langhorne, Orlaith Burke, Rowan H Harwood, Simon P Conroy, Tilo Kircher, Dominique Somme, Ingvild Saltvedt, Heidi Wald, Desmond O'Neill, David Robinson, and Sasha Shepperd

Publish date

2017 Sep;

PMID

31762688

Abstract

We consider the extension of the CMW soft-gluon effective coupling [1] in the context of soft-gluon resummation for QCD hard-scattering observables beyond the next-to-leading logarithmic accuracy. We present two proposals of a soft-gluon effective coupling that extend the CMW coupling to all perturbative orders in the MS⎯⎯⎯⎯⎯⎯ coupling αS. Although both effective couplings are well-defined in the physical four-dimensional space time, we examine their behaviour in d=4−2ϵ space time dimensions. We uncover an all-order perturbative relation with the cusp anomalous dimension: the (four dimensional) cusp anomalous dimension is equal to the d-dimensional soft-gluon effective coupling at the conformal point ϵ=β(αS), where the d-dimensional QCD β-function, β(αS)−ϵ, vanishes. We present the explicit expressions of the two soft-gluon couplings up to (α2S) in d dimensions. In the four-dimensional case we compute the two soft couplings up to (α3S). For one of the two couplings, we confirm the (α3S) result previously presented by other authors. For the other coupling, we obtain the explicit relation with the cusp anomalous dimension up to (α4S). We comment on Casimir scaling at (α4S).

Title

Soft-gluon effective coupling and cusp anomalous dimension

Author

Stefano Catani,1 Daniel de Florian,2 and Massimiliano Grazzinicorresponding author3

Publish date

2019